Tislelizumab Versus Chemotherapy as Second-Line Treatment for Advanced or Metastatic Esophageal Squamous Cell Carcinoma (RATIONALE-302): A Randomized Phase III Study (vol 40, pg 3065, 2022).

被引：0
|
作者：
Shen, Lin
机构：
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2024年 / 42卷 / 04期
关键词：
D O I：
10.1200/JCO.23.02629
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：486 / 486
页数：1
相关论文
共 50 条
  • [41] Randomized, global, phase III study of tislelizumab (TIS) plus chemotherapy (chemo) vs chemo as first-line (1L) therapy for advanced or metastatic esophageal squamous cell carcinoma (ESCC) (RATIONALE-306): Asia subgroup
    Kato, K.
    Yoon, H.
    Raymond, E.
    Hubner, R.
    Shu, Y.
    Pan, Y.
    Park, S. R.
    Ping, L.
    Jiang, Y.
    Zhang, J.
    Wu, X.
    Yao, Y.
    Shen, L.
    Kojima, T.
    Lin, C-Y.
    Wang, L.
    Tao, A.
    Peng, Y.
    Li, L.
    Xu, J.
    ANNALS OF ONCOLOGY, 2022, 33 : S1458 - S1458
  • [42] First-line sugemalimab with chemotherapy for advanced esophageal squamous cell carcinoma: a randomized phase 3 study
    Li, Jin
    Chen, Zhendong
    Bai, Yuxian
    Liu, Bo
    Li, Qingshan
    Zhang, Jingdong
    Zhou, Jun
    Deng, Ting
    Zhou, Fuyou
    Gao, Shegan
    Yang, Shujun
    Ye, Feng
    Chen, Long
    Bai, Wei
    Yin, Xianli
    Cang, Shundong
    Liu, Lianke
    Pan, Yueyin
    Luo, Hui
    Ji, Yanxia
    Zhang, Zhen
    Wang, Jufeng
    Yang, Quanliang
    Li, Na
    Huang, Rong
    Qu, Chenglin
    Ni, Jing
    Wang, Bo
    Xu, Yan
    Hu, Jin
    Shi, Qingmei
    Yang, Jason
    NATURE MEDICINE, 2024, 30 (03) : 740 - 748
  • [43] First-line sugemalimab with chemotherapy for advanced esophageal squamous cell carcinoma: a randomized phase 3 study
    Jin Li
    Zhendong Chen
    Yuxian Bai
    Bo Liu
    Qingshan Li
    Jingdong Zhang
    Jun Zhou
    Ting Deng
    Fuyou Zhou
    Shegan Gao
    Shujun Yang
    Feng Ye
    Long Chen
    Wei Bai
    Xianli Yin
    Shundong Cang
    Lianke Liu
    Yueyin Pan
    Hui Luo
    Yanxia Ji
    Zhen Zhang
    Jufeng Wang
    Quanliang Yang
    Na Li
    Rong Huang
    Chenglin Qu
    Jing Ni
    Bo Wang
    Yan Xu
    Jin Hu
    Qingmei Shi
    Jason Yang
    Nature Medicine, 2024, 30 : 740 - 748
  • [44] Circulating tumor DNA serial monitoring of relapse and responses to tislelizumab immunotherapy as second-line monotherapy for metastatic esophageal squamous cell carcinoma: A prospective study
    He, Qiong
    Shi, Xun
    Yan, Junrong
    Wu, Mengmeng
    Gu, Cuiping
    Yu, Xinmin
    MOLECULAR AND CLINICAL ONCOLOGY, 2024, 20 (04)
  • [45] Comparative efficacy and safety of tislelizumab versus anti-PD-1 treatments in second-line esophageal squamous cell carcinoma: Simulated treatment comparisons
    Smyth, E. C.
    Ajani, J. A.
    Wang, K.
    Castro, J. Coaquira
    Figueiredo, M.
    Sun, J-M.
    Soulanis, K.
    Tasoulas, A.
    Nikolaidis, G.
    Priedane, E.
    Zhan, L.
    ANNALS OF ONCOLOGY, 2024, 35 : S884 - S884
  • [46] Pembrolizumab versus chemotherapy as second-line therapy for advanced esophageal cancer: Phase III KEYNOTE-)181 study.
    Kojima, Takashi
    Muro, Kei
    Francois, Eric
    Hsu, Chih-Hung
    Moriwaki, Toshikazu
    Kim, Sung-Bae
    Lee, Se-Hoon
    Bennouna, Jaafar
    Kato, Ken
    Lin, Shen
    Qin, Shi-Qui
    Ferreira, Paula
    Doi, Toshihiko
    Adenis, Antoine
    Enzinger, Peter C.
    Shah, Manish A.
    Wang, Ruixue
    Bhagia, Pooja
    Kang, S. Peter
    Metges, Jean-Philippe
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (04)
  • [47] Tislelizumab plus chemotherapy versus chemotherapy alone as first-line treatment for advanced squamous non-small-cell lung cancer: final analysis of the randomized, phase III RATIONALE-307 trial
    Wang, J.
    Lu, S.
    Yu, X.
    Hu, Y.
    Zhao, J.
    Sun, M.
    Yu, Y.
    Hu, C.
    Yang, K.
    Song, Y.
    Lin, X.
    Liang, L.
    Leaw, S.
    Zheng, W.
    ESMO OPEN, 2024, 9 (10)
  • [48] JUPITER-06: A randomized, double-blind, phase III study of toripalimab versus placebo in combination with first-line chemotherapy for treatment naive advanced or metastatic esophageal squamous cell carcinoma (ESCC)
    Xu, R-H.
    Wang, F.
    Cui, C.
    Yao, J.
    Zhang, Y.
    Wang, G.
    Feng, J.
    Yang, S.
    Fan, Y.
    Shi, J.
    Zhang, X.
    Shen, L.
    Shu, Y.
    Wang, C.
    Dai, T.
    Mao, T.
    Chen, L.
    Guo, Z.
    Liu, B.
    Pan, H.
    ANNALS OF ONCOLOGY, 2021, 32 : S1041 - S1041
  • [49] Real-World Treatment Patterns and Outcomes in Patients Receiving Second-Line Therapy for Advanced/Metastatic Esophageal Squamous Cell Carcinoma
    Pranav Abraham
    Joe Gricar
    Ying Zhang
    Veena Shankaran
    Advances in Therapy, 2020, 37 : 3392 - 3403
  • [50] Real-World Treatment Patterns and Outcomes in Patients Receiving Second-Line Therapy for Advanced/Metastatic Esophageal Squamous Cell Carcinoma
    Abraham, Pranav
    Gricar, Joe
    Zhang, Ying
    Shankaran, Veena
    ADVANCES IN THERAPY, 2020, 37 (07) : 3392 - 3403
12345